SRA1 and neoplasm: A recent study attempted to enhance tumor delivery of engineered EVs using nonselective SR-A inhibitors; that work showed that inhibition of SR-A reduced the clearance of EVs from liver, resulting in increased accumulation of the engineered EVs in tumors, an effect that would enhance the therapeutic use of such EVs47.